Bouvier N M, Palese P. The biology of influenza viruses [J]. Vaccine, 2008, 26(s4): D49-D53.
[2]
Wang Z, Wan Y, Qiu C, et al. Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8+ T cells [J]. Nat Commun, 2015, 6(5):6833.
Krammer F, Smith G J D, Fouchier R A M, et al. Influenza[J]. Nat Rev Dis Primers, 2018, 4(6):3.
[5]
Moasser E, Moasser A, Zaraket H. Incidence of antiviral drug resistance markers among human influenza A viruses in the Eastern Mediterranean Region, 2005-2016[J]. Infect Genet Evol, 2019, 67(1): 60-66.
Yang J, Liu S, Du L, et al. A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action[J]. Rev Med Virol, 2016, 26(4):242-250.
[8]
Colman P, Varghese J, Laver W. Structure of the catalytic and antigenic sites in influenza virus neuraminidase[J]. Nature, 1983, 303(5912): 41-44.
[9]
Russell R J, Haire L F, Stevens D J, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design [J]. Nature, 2006, 443(7107):45-49.
[10]
Govorkova E A, Leneva I A, Goloubeva O G, et al. Comparison of efcacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian in uenza viruses[J]. Antimicrob Agents Chemother, 2001, 45(10):2723-2732.
[11]
Ikematsu H, Kawai N, Iwaki N, et al. Invitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2016-17 season: Comparison with the 2010-11 to 2015-16 seasons [J]. J Infect Chemother, 2018, 24(9):707-712.
[12]
Alame M M, Elie M, Hassan Z. Peramivir: A novel intravenous neuraminidase inhibitor for treatment of acute influenza infections[J]. Front Microbiol, 2016, 7:1-14.
[13]
Lee N, Hurt A C. Neuraminidase inhibitor resistance in influenza: a clinical perspective [J]. Curr Opin Infect Dis, 2018, 31(6): 520-526.
[14]
Mckimm-Breschkin J L. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance[J]. Influenza Other Respir Viruses, 2013, 7(s1):25-36.
[15]
Govorkova E A, Mccullers J A. Therapeutics against influenza[J]. Curr Top Microbiol Immunol, 2011, 370:273-300.
[16]
Ison M G. Antivirals and resistance: influenza virus[J]. Curr Opin Virol, 2011, 1(6): 563-573.
Moscona A. Neuraminidase inhibitors for influenza[J]. New Engl J Med, 2005, 353(13):1363-1373.
[21]
L’Huillier A G, Ing L K, Crisinel P A, et al. ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia[J]. Pharmacogenomics, 2011, 12(10):1493-1501.
[22]
Nakamura Y, Sugawara T, Ohkusa Y, et al. Life-threatening abnormal behavior incidence in 10-19 year old patients administered neuraminidase inhibitors [J]. PLoS One, 2015, 10(7):e0129712.
[23]
Zaraket H, Saito R. Japanese surveillance systems and treatment for influenza[J]. Curr Treat Options Infect Dis, 2016, 8(4):311-328.
Beau A B, Hurault-Delarue C, Vial T, et al. Safety of oseltamivir during pregnancy: a comparative study using the EFEMERIS database[J]. BJOG-Int J Obstet Gy, 2014, 121(7):895-900.
[26]
Graner S, Svensson T, Beau A B, et al. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study [J]. BMJ, 2017, 356:j629.
[27]
Shi D, Yang J, Yang D, et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel[J]. J Pharmacol Exp Ther, 2006, 319(3):1477-1484.
Ison M G. Clinical use of approved in uenza antivirals: therapy and prophylaxis[J]. Influenza Other Respir Viruses, 2013, 7(s1):7-13.
[30]
Ison M G, Hui D S, Clezy K, et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults[J]. Antivir Ther, 2013, 18(5):651-661.
2019, Vol. 30 
